DK3533447T3 - Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse - Google Patents

Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse Download PDF

Info

Publication number: DK3533447T3
Authority: DK; Denmark
Prior art keywords: bendamustine; administration; treatment; methods; patients requiring
Prior art date: 2012-03-20

Application number

DK19151152.6T

Other languages

English (en)

Inventor

Srikanth Sundaram

Scott L Tarriff

Original Assignee

Eagle Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-20

Filing date

2013-03-15

Publication date

2023-04-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212373&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3533447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-15 Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc

2023-04-24 Application granted granted Critical

2023-04-24 Publication of DK3533447T3 publication Critical patent/DK3533447T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

DK19151152.6T 2012-03-20 2013-03-15 Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse DK3533447T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261613173P	2012-03-20	2012-03-20
US201261669889P	2012-07-10	2012-07-10
US201261678715P	2012-08-02	2012-08-02
EP13765020.6A EP2827863B1 (en)	2012-03-20	2013-03-15	Liquid composition for use in a method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration

Publications (1)

Publication Number	Publication Date
DK3533447T3 true DK3533447T3 (da)	2023-04-24

Family

ID=49212373

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19151152.6T DK3533447T3 (da)	2012-03-20	2013-03-15	Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse
DK13765020.6T DK2827863T3 (da)	2012-03-20	2013-03-15	Flydende sammensætning til anvendelse i en fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter der kræver reducerede volumener til indgivelse

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13765020.6T DK2827863T3 (da)	2012-03-20	2013-03-15	Flydende sammensætning til anvendelse i en fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter der kræver reducerede volumener til indgivelse

Country Status (17)

Country	Link
US (3)	US9000021B2 (da)
EP (3)	EP2827863B1 (da)
JP (6)	JP6224064B2 (da)
CN (2)	CN104271135B (da)
CA (1)	CA2867343C (da)
DK (2)	DK3533447T3 (da)
ES (2)	ES2943668T3 (da)
FI (1)	FI3533447T3 (da)
HK (1)	HK1243346A1 (da)
HR (2)	HRP20230276T1 (da)
HU (2)	HUE044233T2 (da)
LT (1)	LT2827863T (da)
PL (2)	PL2827863T3 (da)
PT (2)	PT2827863T (da)
RS (2)	RS58744B1 (da)
SI (2)	SI2827863T1 (da)
WO (1)	WO2013142359A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3158991T3 (pl)	2010-01-28	2021-09-27	Eagle Pharmaceuticals, Inc.	Preparaty bendamustyny
CN104271135B (zh)	2012-03-20	2017-05-17	赛多斯有限责任公司	在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法
SI2827862T1 (sl) *	2012-03-20	2024-03-29	Eagle Pharmaceuticals, Inc.	Formulacije bendamustina
US20230241218A1 (en) *	2012-07-10	2023-08-03	Eagle Pharmaceuticals, Inc.	Formulations of bendamustine
US11826466B2 (en)	2016-08-31	2023-11-28	Navinta, Llc	Bendamustine solution formulations
US10905677B2 (en)	2016-08-31	2021-02-02	Navinta, Llc	Bendamustine solution formulations
US11730815B2 (en) *	2018-11-26	2023-08-22	Good Health, Llc	Stable liquid pharmaceutical compositions comprising bendamustine
JP7235288B2 (ja) *	2019-01-07	2023-03-08	コーアイセイ株式会社	ベンダムスチンの液体製剤
CN110123747A (zh) *	2019-04-26	2019-08-16	嘉兴市爵拓科技有限公司	苯达莫司汀的制剂
JPWO2021014957A1 (da) *	2019-07-22	2021-01-28
WO2021161876A1 (ja) *	2020-02-10	2021-08-19	富士フイルム株式会社	ベンダムスチン液剤
US20240148696A1 (en)	2022-10-25	2024-05-09	Softkemo Pharma Inc.	Lyophilized bendamustine-cyclodextrin composition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE159289C (da)	1903-10-08	1905-03-16
US4071620A (en)	1977-01-10	1978-01-31	American Home Products Corporation	Stabilization of oxygen sensitive dose forms
DD159289A1 (de)	1981-06-01	1983-03-02	Uwe Olthoff	Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DE3446873A1 (de)	1984-12-21	1986-07-10	Merckle Gmbh	Fluessige diclofenac-zubereitungen
US5223515A (en)	1988-08-18	1993-06-29	Takeda Chemical Industries, Ltd.	Injectable solution containing a pyridyl methylsulfinylbenzimidazole
CA2181241C (en)	1994-01-24	2000-04-25	Dadi Jamshed Dhabhar	Process for solubilizing difficultly soluble pharmaceutical actives
ATE526022T1 (de)	1998-04-20	2011-10-15	Eisai R&D Man Co Ltd	Stabilisierte zusammenstellungen die benzimidazole enthalten
AU2001211213A1 (en)	2000-10-20	2002-04-29	Galephar M/F	Stable oral formulation containing benzimidazole derivative
NZ537829A (en)	2002-07-30	2006-09-29	Wyeth Corp	Parenteral formulations containing a rapamycin hydroxyester
US20060035945A1 (en)	2003-05-30	2006-02-16	Giorgio Attardo	Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
SE0401842D0 (sv) *	2004-07-12	2004-07-12	Dizlin Medical Design Ab	Infusion and injection solution of levodopa
CN101933923A (zh)	2004-11-05	2011-01-05	赛福伦公司	癌症治疗
US8436190B2 (en)	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
KR20080039954A (ko) *	2005-08-31	2008-05-07	오노 야꾸힝 고교 가부시키가이샤	점적용 주사제
EP2052723A4 (en)	2006-08-14	2010-07-28	Eisai R&D Man Co Ltd	STABLE LYOPHILIZED PREPARATION
WO2008044029A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
DE102007003184A1 (de)	2007-01-22	2008-07-24	Orlowski, Michael, Dr.	Verfahren zur Beladung von strukturierten Oberflächen
US20090082416A1 (en)	2007-09-25	2009-03-26	Protia, Llc	Deuterium-enriched bendamustine
AR072777A1 (es)	2008-03-26	2010-09-22	Cephalon Inc	Formas solidas de clorhidrato de bendamustina
MX2011002936A (es)	2008-09-25	2011-04-11	Cephalon Inc	Formulaciones liquidas de bendamustina.
CA2749101A1 (en)	2009-01-15	2010-07-22	Cephalon, Inc.	Novel forms of bendamustine free base
CN102421451B (zh)	2009-02-25	2013-11-06	休普拉特克药品有限公司	苯达莫司汀环多糖组合物
US20100273730A1 (en)	2009-04-27	2010-10-28	Innopharmax, Inc.	Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CN102413816A (zh)	2009-04-28	2012-04-11	赛福伦公司	苯达莫司汀的口服制剂
CN101584668A (zh) *	2009-06-19	2009-11-25	江苏奥赛康药业有限公司	盐酸苯达莫司汀冻干粉针剂
WO2010148288A2 (en)	2009-06-19	2010-12-23	Lyotropic Therapeutics, Inc.	Pharmaceutical formulations with low aqueous levels of free unbound drug
US20110015245A1 (en)	2009-07-20	2011-01-20	Valery Alakhov	Bendamustine amphiphilic cationic compositions
US8389558B2 (en)	2009-07-20	2013-03-05	Supratek Pharma Inc.	Bendamustine amphiphilic anionic compositions
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
PL3158991T3 (pl) *	2010-01-28	2021-09-27	Eagle Pharmaceuticals, Inc.	Preparaty bendamustyny
WO2011146882A1 (en) *	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
US9655898B2 (en)	2010-07-28	2017-05-23	Eagle Pharmaceuticals, Inc.	Pharmaceutical compositions containing pemetrexed having extended storage stability
JP6483442B2 (ja)	2011-12-05	2019-03-13	エックス−ボディインコーポレイテッド	Ｐｄｇｆ受容体ベータ結合ポリペプチド
US20130210878A1 (en) *	2012-01-24	2013-08-15	Innopharma, Inc.	Bendamustine compositions and methods therefore
EP2814487A4 (en)	2012-02-14	2015-07-15	Eagle Pharmaceuticals Inc	BENDAMUSTIN FORMULATIONS
SI2827862T1 (sl)	2012-03-20	2024-03-29	Eagle Pharmaceuticals, Inc.	Formulacije bendamustina
CN104271135B (zh)	2012-03-20	2017-05-17	赛多斯有限责任公司	在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法

2013
- 2013-03-15 CN CN201380023660.5A patent/CN104271135B/zh not_active Expired - Fee Related
- 2013-03-15 PT PT13765020T patent/PT2827863T/pt unknown
- 2013-03-15 PL PL13765020T patent/PL2827863T3/pl unknown
- 2013-03-15 HU HUE13765020 patent/HUE044233T2/hu unknown
- 2013-03-15 DK DK19151152.6T patent/DK3533447T3/da active
- 2013-03-15 PL PL19151152.6T patent/PL3533447T3/pl unknown
- 2013-03-15 US US13/838,267 patent/US9000021B2/en active Active
- 2013-03-15 PT PT191511526T patent/PT3533447T/pt unknown
- 2013-03-15 JP JP2015501814A patent/JP6224064B2/ja active Active
- 2013-03-15 RS RS20190433A patent/RS58744B1/sr unknown
- 2013-03-15 SI SI201331394T patent/SI2827863T1/sl unknown
- 2013-03-15 RS RS20230252A patent/RS64137B1/sr unknown
- 2013-03-15 EP EP13765020.6A patent/EP2827863B1/en active Active
- 2013-03-15 EP EP19151152.6A patent/EP3533447B1/en active Active
- 2013-03-15 HU HUE19151152A patent/HUE062230T2/hu unknown
- 2013-03-15 WO PCT/US2013/032295 patent/WO2013142359A1/en active Application Filing
- 2013-03-15 HR HRP20230276TT patent/HRP20230276T1/hr unknown
- 2013-03-15 SI SI201332039T patent/SI3533447T1/sl unknown
- 2013-03-15 LT LTEP13765020.6T patent/LT2827863T/lt unknown
- 2013-03-15 ES ES19151152T patent/ES2943668T3/es active Active
- 2013-03-15 EP EP23161418.1A patent/EP4218756A1/en active Pending
- 2013-03-15 DK DK13765020.6T patent/DK2827863T3/da active
- 2013-03-15 ES ES13765020T patent/ES2718902T3/es active Active
- 2013-03-15 CN CN201710292508.7A patent/CN107157988A/zh active Pending
- 2013-03-15 CA CA2867343A patent/CA2867343C/en active Active
2014
- 2014-11-26 US US14/554,269 patent/US20150080444A1/en not_active Abandoned
2015
- 2015-03-15 FI FIEP19151152.6T patent/FI3533447T3/fi active
- 2015-08-06 US US14/820,291 patent/US9579384B2/en active Active
2017
- 2017-10-04 JP JP2017193917A patent/JP6381761B2/ja active Active
2018
- 2018-02-28 HK HK18102930.9A patent/HK1243346A1/zh unknown
- 2018-07-31 JP JP2018143022A patent/JP6738376B2/ja active Active
2019
- 2019-04-12 HR HRP20190693TT patent/HRP20190693T1/hr unknown
2020
- 2020-05-29 JP JP2020093802A patent/JP2020143143A/ja active Pending
2021
- 2021-11-17 JP JP2021186829A patent/JP2022028813A/ja active Pending
2023
- 2023-12-15 JP JP2023212014A patent/JP2024037915A/ja active Pending

Also Published As

Publication number	Publication date
DK2827863T3 (da)	2019-04-23
HUE044233T2 (hu)	2019-10-28
ES2943668T3 (es)	2023-06-15
EP3533447A1 (en)	2019-09-04
PL3533447T3 (pl)	2023-07-17
JP2024037915A (ja)	2024-03-19
CA2867343A1 (en)	2013-09-26
JP2022028813A (ja)	2022-02-16
CA2867343C (en)	2020-08-11
US9579384B2 (en)	2017-02-28
SI2827863T1 (sl)	2019-06-28
RS58744B1 (sr)	2019-06-28
CN107157988A (zh)	2017-09-15
US20150080444A1 (en)	2015-03-19
US20150343061A1 (en)	2015-12-03
JP6224064B2 (ja)	2017-11-01
EP2827863B1 (en)	2019-01-16
FI3533447T3 (fi)	2023-05-04
HRP20230276T1 (hr)	2023-04-28
WO2013142359A1 (en)	2013-09-26
EP2827863A1 (en)	2015-01-28
JP6381761B2 (ja)	2018-08-29
CN104271135A (zh)	2015-01-07
US20130253026A1 (en)	2013-09-26
ES2718902T3 (es)	2019-07-05
JP2015510940A (ja)	2015-04-13
PL2827863T3 (pl)	2019-07-31
EP2827863A4 (en)	2015-11-18
US9000021B2 (en)	2015-04-07
PT2827863T (pt)	2019-05-13
JP2020143143A (ja)	2020-09-10
PT3533447T (pt)	2023-05-17
JP2018197248A (ja)	2018-12-13
HK1243346A1 (zh)	2018-07-13
CN104271135B (zh)	2017-05-17
RS64137B1 (sr)	2023-05-31
SI3533447T1 (sl)	2023-06-30
EP3533447B1 (en)	2023-03-15
HUE062230T2 (hu)	2023-10-28
JP2018048153A (ja)	2018-03-29
EP4218756A1 (en)	2023-08-02
JP6738376B2 (ja)	2020-08-12
HRP20190693T1 (hr)	2019-10-04
LT2827863T (lt)	2019-06-10

Publication	Publication Date	Title
DK3533447T3 (da)	2023-04-24	Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse
DK3632919T3 (da)	2022-11-14	Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering
DK2773648T3 (da)	2019-05-20	Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion
DK2938740T3 (da)	2022-06-20	Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK3329909T3 (da)	2021-04-19	Fenfluramin til anvendelse i behandling af dravet syndrom
CO6852068A2 (es)	2014-01-30	Formulación líquida estable de etanercept
DK2877574T3 (da)	2019-08-05	Alpha (1,2)-fucosyltransferaser egnet til anvendelse i fremstillingen af fucosylerede oligosaccharider
DK3329884T3 (da)	2021-09-13	Implanterbar indretning til behandling af glaukom
DK3730136T3 (da)	2024-01-22	Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
BR112014028602A2 (pt)	2017-06-27	formulação líquida.
DK2844279T3 (da)	2021-03-15	Doseringsprogrammer til behandling af pompes sygdom
DK3050972T3 (da)	2021-02-08	Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
DK3040336T3 (da)	2020-06-22	Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
FR2987746B1 (fr)	2015-04-10	Seringue pour application medicale
DK2869836T3 (da)	2019-11-25	Dna-vaccine til anvendelse hos patienter med pankreascancer
DK2891494T3 (da)	2023-10-23	Fremgangsmåde til administration af hypnotisserende/beroligende midler
DK3234107T3 (da)	2022-10-17	B-celler til in vivo-levering af terapeutiske midler
DK2836203T3 (da)	2022-06-07	Vesikulær formulering til anvendelse til behandling af smerter eller nedsat mobilitet i et led
DK2914310T3 (da)	2020-07-27	Medicinske indretninger med coatings til forbedret ekkogenicitet
DK3456334T3 (da)	2021-01-25	Mælkesyrebakterier til anvendelse i forebyggelse af knogletab hos pattedyr
BR112016014512A2 (pt)	2018-05-22	formulações farmacêuticas líquidas de pemetrexede
EP2902052A4 (en)	2016-05-18	MEDICAL LIQUID ADMINISTRATION DEVICE
DK2735305T3 (da)	2021-11-15	Stabiliserede flydende farmaceutiske præparater
DK2938350T3 (da)	2019-07-15	Medicinsk formulering til behandling af hypercholesterolæmi
ITRM20120530A1 (it)	2014-05-01	Compounds for use in the treatment of parasitic diseases